Clinical analysis of allogenic bone marrow derived mesenchymal stem cells transplantation for 11 patients with systemic lupus erythematosus
10.3760/cma.j.issn.1007-7480.2009.02.005
- VernacularTitle:异基因骨髓间充质干细胞移植治疗系统性红斑狼疮11例临床分析
- Author:
Huayong ZHANG
;
Xuebing FENG
;
Xiaolei MA
;
Bujun LIU
;
Hong WANG
;
Bingzhu HUA
;
Ting XU
;
Shengnan ZHAO
;
Jie WANG
;
Jianyong LI
;
Lingyun SUN
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus,systemic;
Mesenchymal stem cell transplantation
- From:
Chinese Journal of Rheumatology
2009;13(2):89-92
- CountryChina
- Language:Chinese
-
Abstract:
Objeefive To explore the clinical efficacy and safety of allogenic bone marrow derived mesenchymal stem cells transplantation(MSCT) in patients with refractory systemic lupus erythematosus(SLE).Methods Eleven patients with refractory SLE(nine females and two males aged from 16～41 years(mean 25±8).were entailed in the study.The infcIrmed consents which were approved by the Ethics Committee of the Affiliated Drum Tower Hospital of Naniing University Medical School were obtained from all participants.Bone marrow of healthy donors were obtained and the mesenchymal stem cells(MSC)were expanded in vitro.Each patient was infused MSC 1×106/kg body weight intravenously.Before MSCT.all patients were administrated with cvclophosphamide (CTX)800～1800 mg divided by two to three days.The clinical manifestations and laboratory tests were compared before and after MSCT.Results The eleven patients were followed up for one to thirteen months after MSCT.A11 patients did not develop transplantation related complications.The systemic lupus erythematosus disease activity index (SLEDAI)score decreased from 1 1.7±5.1 to 5.6±3.4 one month after MSCT(n=11,P＜0.01).Ufine protein excretion decreased from(1989+842)mg/24 h to(1118±700)mg/24 h one month after MSCT(n=10,P=0.02).Five patients were followed up for six months and their urine protein excretion decreased significantly [(522±151)mg/24 h vs (2478±797)rag/24 h.n=5.P＜0.01j.The serum albumin level of 5 patients with hypoalbuminemia increased gradually one month after MSCT [(28±6)g/L vs (32±7)g/L,n=5,P＜0.05].Serum complement C3 level increased from(0.50±0.12) g/L to(0.75±0.10)g/L (n=9.P＜0.01) and their anti-nuclear antibody (ANA) titer decreased one month after MSCT.In two patients with chronic renal failure.the serum creatinine decreased gradually.Conclusion Allogenic MSCT is an effective and safe approach for the treatment of refractory SLE.However.extensive follow-up study is needed for long-term benefit evaluation.
